Cargando…

Latency Reversing Agents: Kick and Kill of HTLV-1?

Human T-cell leukemia virus type 1 (HTLV-1), the cause of adult T-cell leukemia/lymphoma (ATLL), is a retrovirus, which integrates into the host genome and persistently infects CD4(+) T-cells. Virus propagation is stimulated by (1) clonal expansion of infected cells and (2) de novo infection. Viral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnell, Annika P., Kohrt, Stephan, Thoma-Kress, Andrea K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197370/ https://www.ncbi.nlm.nih.gov/pubmed/34073995 http://dx.doi.org/10.3390/ijms22115545

Ejemplares similares

HDAC inhibitors Panobinostat and Romidepsin enhance tax transcription in HTLV-1-infected cell lines and freshly isolated patients’ T-cells
por: Schnell, Annika P., et al.
Publicado: (2022)

Landscape review of current HIV ‘kick and kill’ cure research - some kicking, not enough killing
por: Thorlund, Kristian, et al.
Publicado: (2017)

Molecular Mechanisms of HTLV-1 Cell-to-Cell Transmission
por: Gross, Christine, et al.
Publicado: (2016)

Characterizing the Interaction between the HTLV-1 Transactivator Tax-1 with Transcription Elongation Factor ELL2 and Its Impact on Viral Transactivation
por: Kohrt, Stephan, et al.
Publicado: (2021)

Regulation of Expression and Latency in BLV and HTLV
por: Pluta, Aneta, et al.
Publicado: (2020)

Silencers of HTLV-1 and HTLV-2: the pX-encoded latency-maintenance factors
por: Harrod, Robert
Publicado: (2019)

Milk Transmission of HTLV-1 and the Need for Innovative Prevention Strategies
por: Millen, Sebastian, et al.
Publicado: (2022)

Clonality, latency and integration of HTLV-1 in vivo
por: Bangham, Charles, et al.
Publicado: (2013)

Modeling Kick-Kill Strategies toward HIV Cure
por: Hernandez-Vargas, Esteban A.
Publicado: (2017)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

Quantitating the Transfer of the HTLV-1 p8 Protein Between T-Cells by Flow Cytometry
por: Donhauser, Norbert, et al.
Publicado: (2018)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
por: Lewis, Catherine A., et al.
Publicado: (2023)

Cell Surface Markers in HTLV-1 Pathogenesis
por: Kress, Andrea K., et al.
Publicado: (2011)

HTLV-1: Regulating the Balance Between Proviral Latency and Reactivation
por: Kulkarni, Anurag, et al.
Publicado: (2018)

Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency
por: Covino, Daniela A., et al.
Publicado: (2021)

p30 protein: a critical regulator of HTLV-1 viral latency and host immunity
por: Moles, Ramona, et al.
Publicado: (2019)

The Effect of Latency Reversal Agents on Primary CD8 + T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication
por: Walker-Sperling, Victoria E., et al.
Publicado: (2016)

New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models
por: Bricker, Katherine M., et al.
Publicado: (2021)

Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
por: Salahong, Thanarat, et al.
Publicado: (2021)

Impact of latency‐reversing agents on human macrophage physiology
por: Hany, Laurent, et al.
Publicado: (2022)

Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents
por: Delagrèverie, Héloïse M., et al.
Publicado: (2016)

Targeting HTLV-I latency in Adult T-cell Leukemia/Lymphoma
por: Ramos, Juan C, et al.
Publicado: (2011)

Reanalysis of Gene Expression Profiles of CD4+ T Cells Treated with HIV-1 Latency Reversal Agents
por: Campos Coelho, Antonio Victor, et al.
Publicado: (2020)

The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review
por: Debrabander, Quinten, et al.
Publicado: (2023)

AHR is a tunable knob that controls HTLV-1 latency-reactivation switching
por: Hong, Weihao, et al.
Publicado: (2020)

NSC95397 is a Novel HIV Latency Reversing Agent
por: Nichols Doyle, Randilea, et al.
Publicado: (2023)

Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA
por: Taylor, Jared P., et al.
Publicado: (2020)

A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells
por: Wang, Xinling, et al.
Publicado: (2022)

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
por: Clutton, G., et al.
Publicado: (2016)

Comparative virology of HTLV-1 and HTLV-2
por: Martinez, Michael P., et al.
Publicado: (2019)

A novel positive feedback-loop between the HTLV-1 oncoprotein Tax and NF-κB activity in T-cells
por: Millen, Sebastian, et al.
Publicado: (2020)

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents
por: Gupta, Vipul, et al.
Publicado: (2018)

Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents
por: Sorensen, Eric S., et al.
Publicado: (2020)

Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents
por: Li, Rui, et al.
Publicado: (2023)

The role of latency reversal in HIV cure strategies
por: Tanaka, Kiho, et al.
Publicado: (2022)

HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies
por: Khanal, Sushant, et al.
Publicado: (2021)

Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen
por: Liu, Hongbing, et al.
Publicado: (2021)

Transfer of HTLV-1 p8 and Gag to target T-cells depends on VASP, a novel interaction partner of p8
por: Donhauser, Norbert, et al.
Publicado: (2020)

Tumor suppressor in lung cancer identifies latency infected cells in non malignant HTLV-1 infection
por: Manivannan, Kiruthika, et al.
Publicado: (2015)

Diversity of small molecule HIV‐1 latency reversing agents identified in low‐ and high‐throughput small molecule screens
por: Hashemi, Pargol, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e9oudpvegdlagp0l1gdianja0e